HOME >> MEDICINE >> NEWS
Gene mutations predict which lung cancers will respond to Iressa

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have discovered a molecular marker that identifies lung cancer patients whose tumors will respond to treatment with the drug Iressa (gefitinib). Their findings, which will be published in the May 20 New England Journal of Medicine, are being released online today to coincide with the online release by Science of related research from Dana-Farber Cancer Institute.

"This discovery will help us significantly improve the treatment of many lung cancer patients and is also an important next step in the molecular targeting of cancer drugs," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the NEJM paper. "We're hopeful that what we have learned will eventually lead to more new drugs that will target tumor-specific mutations without affecting normal tissues."

Iressa was approved a year ago for the treatment of advanced non-small-cell lung cancer (NSCLC), a tumor that is particularly difficult to treat and is the leading cause of cancer deaths in the U.S. In a major clinical trial Iressa caused tumors to shrink significantly in only 13.6 percent of patients, but some of those responses were rapid and dramatic. As a result, the FDA approved the drug because there are no other treatment options for NSCLC patients for whom standard chemotherapy has failed.

Iressa acts by disabling the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, halting a sequence of signals that can lead to the uncontrolled growth characterizing a malignant tumor. In their search for an answer to why the drug worked so well for some NSCLC patients but was of no assistance to others, the MGH team screened tumor samples from MGH patients who participated in the Iressa clinical trial to search for mutations in the EGFR gene.

Initial analysis found mutations affecting the same area (the ATP cleft of the kinase domain) of the receptor prot
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
29-Apr-2004


Page: 1 2 3

Related medicine news :

1. Non-invasive and invasive breast cancers share the same genetic mutations
2. Both inherited traits and tumor mutations affect response to treatment of leukemia
3. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
4. Gene mutations responsible for childhood cataracts discovered
5. Breast cancer patients with BRCA1 or 2 mutations twice as likely to have double mastectomy
6. Breast cancer patients with BRCA 1/2 mutations twice as likely to choose double mastectomy
7. Mayo Clinic researchers discover gene mutations that ignore stress, lead to heart failure
8. In 15 seconds, new test will ID presence of 25 most common mutations of cystic fibrosis
9. Northwestern on trail of gene mutations that trigger sex reversal
10. Gene mutations found that lead to prostate cancer in mice new mouse model developed to study the disease
11. New evaluation tool reliably predicts recovery from coma

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene mutations predict which lung cancers will respond Iressa

(Date:7/5/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... that effectively removes weeds without harming man and nature. , "The Landscaping Services ... Director of World Patent Marketing. "It is projected to grow at an annualized ...
(Date:7/4/2015)... , ... July 04, 2015 , ... ... Surgeons published the results of an annual member survey , detailing the ... States. More recently, the group broke that raw data down into charts detailing ...
(Date:7/3/2015)... ... ... Food Bank will hopefully be getting a large donation of canned food items at ... SC are making it their mission to collect as many canned items as possible. Donations ... the public as well. As part of the canned food drive, these local chiropractors will ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers believe ... asbestos exposure. Click here to read the complete story , just posted on ... Cedars Sinai Medical Center, and New York University exposed mice with a mutation on ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy ... injured bicyclists and practical points of investigating these types of cases. , Each ...
Breaking Medicine News(10 mins):Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2
(Date:7/2/2015)... Pharma Major Lupin Limited today announced the acquisition of ... subject to certain closing conditions. The acquisition marks ... 765 billion in sales, placing it as one of the ... Health). For over a decade, Russian pharmaceutical market recorded double ... Russia to be one of the ...
(Date:7/2/2015)... N.C. , July 2, 2015 ... assets related to the ion channel biology platform from ... been obtained as part of Pfizer,s 2011 acquisition of ... rights to the "Icagen" name and trademark.  XRPro Sciences ... services for ion channel and transporter drug discovery, combining ...
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
Cached News: